Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Specialized Stem Cell Transplant Product (CD34+ Selected Donor Cells) for the Treatment of Low Blood Counts after Donor Stem Cell Transplant

Trial Status: active

This clinical trial tests how well CD34+ selected donor cells work in treating low blood counts after donor stem cell transplant (poor graft function or graft failure). In many instances, donor stem cell transplant represents the only therapy that offers a cure for underlying disease conditions. Successful transplant depends on engraftment, in which donor blood cells replace the patient's blood cells at normal levels. However, engraftment is not achieved for all patients and poor graft function or graft failure can occur. Poor graft function or graft failure is a serious complication of transplant. The usual treatments for poor graft function or graft failure are rarely successful. New therapies are needed to help treat poor graft function or graft failure. Using CD34+ selected donor cells may be a useful treatment for poor graft function of graft failure. In this trial, donor stem cells are collected and then processed using the CliniMACS® CD34 Reagent System. The CliniMACS® CD34 Reagent System isolates CD34+ cells and separates CD34+ donor cells from donor T-cells. The CD34+ and T-cells are separated so patients can receive only the CD34+ cells and not the T-cells. Patients receiving additional T-cells could increase the chance of another transplant complication, graft versus host disease (GVHD), or other GVHD related complications. CD34+ cells are responsible for creating white blood cells that fight infections, red blood cells that carry oxygen throughout the body, and platelets that prevent bleeding. The infusion of CD34+ cells may help poor graft function or graft failure by creating normal levels of white and red blood cells and reduce or eliminate the need for additional medications to promote the development of blood cells as well as blood and platelet transfusions. Giving CD34+ selected donor cells may be safe and effective in treating patients with poor graft function or graft failure.